GSK’s Relvar Ellipta hits the mark in COPD trial
A “ground-breaking” UK study has shown that GlaxoSmithKline’s Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Read More
